IGI Logo

Below are Views On Should retail investors invest in pharma IPO of Nureca limited? By Mr. Yash Gupta Equity Research Associate, Angel Broking Ltd   

After the pharma outperformed the major indices in FY2020, should retail investors invest in Nureca limited?

Nureca limited is a B2C company engaged in the business of home healthcare and wellness products. The company enables their customers with tools to help them monitor chronic ailments and other diseases, to improve their lifestyle. Nureca is a digital first company wherein they sell their products through online channel partners such as e-commerce players, distributors and retailer. Further, they also sell their products through their own website drtrust.in.

Nureca classifies their products portfolio under the 5 categories such as Chronic Device Products, Orthopedic Products, Mother and Child Products, Nutrition Supplements and Lifestyle Products.

During Covid-19, company’s products such as oximeter, gluco meter, nebulizer and BP monitor were categorized under the essential goods and their operations were not shut down during this pandemic.

On valuation front, company is coming up with IPO at price of 400 crores with PE levels of 43.7 on FY2020 basis, even company has done very well in first half of FY2021 also due to covid 19.

We have a positive outlook for the IPO.

Above views are of the author and not of the website kindly read disclaimer